A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
- Author:
Jun Ho YI
1
;
Jung Hun KANG
;
In Gyu HWANG
;
Hee Kyung AHN
;
Hyun Jin BAEK
;
Soon Il LEE
;
Do Hyoung LIM
;
Young Woong WON
;
Jun Ho JI
;
Hyo Song KIM
;
Sun Young RHA
;
Sung Yong OH
;
Kyung Eun LEE
;
Taekyu LIM
;
Chi Hoon MAENG
;
Moon Jin KIM
;
Seung Tae KIM
;
Jeeyun LEE
;
Joon Oh PARK
;
Young Suk PARK
;
Ho Yeong LIM
;
Won Ki KANG
;
Se Hoon PARK
Author Information
- Publication Type:Original Article
- Keywords: Stomach neoplasms; ErbB-2 receptor; Trastuzumab; Histology; Ethnic groups
- MeSH: Adenocarcinoma; Asian Continental Ancestry Group; Carcinoma, Signet Ring Cell; Disease-Free Survival; Drug Therapy*; Ethnic Groups; Humans; Receptor, erbB-2; Retrospective Studies*; Stomach Neoplasms*
- From:Cancer Research and Treatment 2016;48(2):553-560
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. MATERIALS AND METHODS: Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. RESULTS: A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). CONCLUSION: While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
